548 related articles for article (PubMed ID: 24937702)
1. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
3. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
5. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
6. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
7. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
8. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
16. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Zhang DM; Shu C; Chen JJ; Sodani K; Wang J; Bhatnagar J; Lan P; Ruan ZX; Xiao ZJ; Ambudkar SV; Chen WM; Chen ZS; Ye WC
Mol Pharm; 2012 Nov; 9(11):3147-59. PubMed ID: 23046348
[TBL] [Abstract][Full Text] [Related]
17. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
[TBL] [Abstract][Full Text] [Related]
18. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
19. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
20. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
